Selected adipocytokine concentrations in patients hospitalized for exacerbated chronic heart failure
Abstract
Introduction: The role of adipose tissue as energy storage and endocrine organ is an area of interest in the treatment of several diseases. This study aimed to to evaluate blood adiponectin (ADP), leptin, tumor necrosis factor type alpha (TNF-alpha) concentrations, and their prognostic value in patients with exacerbated chronic heart failure (CHF).
Methods and results: The following were assessed in 64 consecutive patients hospitalized for exacerbated CHF and a control group of 32 age and sex-matched individuals admitted due to life-limiting symptoms of peripheral artery disease: serum leptin, ADP, TNF-alpha concentrations, and body composition determined by bioelectrical impedance analysis. Compared to the control group, CHF patients had significantly higher blood ADP concentrations, a higher ratio of ADP to fat mass expressed as a percentage of body mass, and lower blood TNF-alpha concentrations and ratios of TNF-alpha to the visceral fat level (VFL). Compared to patients who survived, patients with CHF who died during the one-year follow-up had significantly higher values of ADP and higher ratios of ADP to body surface area. In the Cox regression model, blood ADP concentration was the only independent risk factor in respect of all-cause mortality during the one-year follow-up (HR; 95% CI: 1.16; 1.03-1.31).
Conclusions: Patients with CHF present dysregulation in the secretion of ADP and TNF-alpha. Increased blood ADP concentration was associated with an increase in one-year all-cause mortality by 16%.
Keywords: chronic heart failureadipocytokinesadiponectintumor necrosis factor alphaleptinprognosis
References
- Wawrzeńczyk A, Anaszewicz M, Wawrzeńczyk A, et al. Clinical significance of nutritional status in patients with chronic heart failure-a systematic review. Heart Fail Rev. 2019; 24(5): 671–700.
- Mocan M, Mocan Hognogi LD, Anton FP, et al. Biomarkers of inflammation in left ventricular diastolic dysfunction. Dis Markers. 2019; 2019: 7583690.
- Hanna A, Frangogiannis NG. Inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc Drugs Ther. 2020; 34(6): 849–863.
- El Missiri AM, Alzurfi AS, Keddeas VW. The relationship between tumor necrosis factor alpha and left ventricular diastolic function. J Cardiovasc Echogr. 2020; 30(2): 62–67.
- Rostoff P, Siniarski A, Haberka M, et al. Relationship among the leptin-to-adiponectin ratio, systemic inflammation, and anisocytosis in well-controlled type 2 diabetic patients with atherosclerotic cardiovascular disease. Kardiol Pol. 2020; 78(5): 420–428.
- Poetsch MS, Strano A, Guan K. Role of Leptin in Cardiovascular Diseases. Front Endocrinol (Lausanne). 2020; 11: 354.
- Sawaguchi T, Nakajima T, Haruyama A, et al. Association of serum leptin and adiponectin concentrations with echocardiographic parameters and pathophysiological states in patients with cardiovascular disease receiving cardiovascular surgery. PLoS One. 2019; 14(11): e0225008.
- Dadarlat-Pop A, Pop D, Procopciuc L, et al. Leptin, galectin-3 and angiotensin II type 1 receptor polymorphism in overweight and obese patients with heart failure - role and functional interplay. Int J Gen Med. 2021; 14: 1727–1737.
- Kita S, Shimomura I. Stimulation of exosome biogenesis by adiponectin, a circulating factor secreted from adipocytes. J Biochem. 2021; 169(2): 173–179.
- Shimada YJ. Is leptin protective against heart failure with preserved ejection fraction? A complex interrelationship among leptin, obesity, and left ventricular hypertrophy. Hypertens Res. 2019; 42(2): 141–142.
- Ahiante BO, Smith W, Lammertyn L, et al. Leptin and the vasculature in young adults: The African-PREDICT study. Eur J Clin Invest. 2019; 49(1): e13039.
- Mado H, Szczurek W, Gąsior M, et al. Adiponectin in heart failure. Future Cardiol. 2021; 17(4): 757–764.
- Lakshmanan S, Jankowich M, Wu WC, et al. Association of plasma adiponectin with pulmonary hypertension, mortality and heart failure in African Americans: Jackson Heart Study. Pulm Circ. 2020; 10(4): 2045894020961242.
- Jauhiainen R, Jauhiainen M, Vangipurapu J, et al. Novel biomarkers associated with incident heart failure in 10 106 Finnish men. ESC Heart Fail. 2021; 8(1): 605–614.
- Luo D, Chen P, Yang Z, et al. High plasma adiponectin is associated with increased pulmonary blood flow and reduced right ventricular function in patients with pulmonary hypertension. BMC Pulm Med. 2020; 20(1): 204.
- Horbal SR, Hall ME, Dinh PC, et al. Associations of adiponectin and leptin with brain natriuretic peptide in African Americans: the Jackson Heart Study. Cardiovasc Endocrinol Metab. 2020; 9(2): 49–55.
- Monzo L, Kotrc M, Benes J, et al. Clinical and humoral determinants of congestion in heart failure: potential role of adiponectin. Kidney Blood Press Res. 2019; 44(5): 1271–1284.
- Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18(8): 891–975.
- Mayer O, Seidlerová J, Bruthans J, et al. Is there really an association of high circulating adiponectin concentration and mortality or morbidity risk in stable coronary artery disease? Horm Metab Res. 2020; 52(12): 861–868.
- Nakamura Y, Kita S, Tanaka Y, et al. Adiponectin stimulates exosome release to enhance mesenchymal stem-cell-driven therapy of heart failure in mice. Mol Ther. 2020; 28(10): 2203–2219.
- Sagris M, Theofilis P, Antonopoulos AS, et al. Inflammation in Coronary Microvascular Dysfunction. Int J Mol Sci. 2021; 22(24).
- Vichinsartvichai P, Teeramara R, Jirasawas T, et al. Comparison of urinary adiponectin in the presence of metabolic syndrome in peri- and postmenopausal women. BMC Womens Health. 2022; 22(1): 70.
- Henning RJ. Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. Am J Cardiovasc Dis. 2021; 11(4): 504–529.
- Hanna A, Frangogiannis NG. Inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc Drugs Ther. 2020; 34(6): 849–863.
- Albar Z, Albakri M, Hajjari J, et al. Inflammatory markers and risk of heart failure with reduced to preserved ejection fraction. Am J Cardiol. 2022; 167: 68–75.
- Chaikijurajai T, Tang WH. Reappraisal of inflammatory biomarkers in heart failure. Curr Heart Fail Rep. 2020; 17(1): 9–19.
- Roytman AP, Sedova NA, Ivanova EA, et al. The importance of laboratory parameters of the lipid transport system and adipose tissue hormones in assessing the course of chronic. Klin Lab Diagn. 2022; 67(2): 85–90.
- Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019; 74(10): 1376–1414.
- Chamberlain AM, Cohen SS, Weston SA, et al. Relation of cardiovascular events and deaths to low-density lipoprotein cholesterol level among statin-treated patients with atherosclerotic cardiovascular disease. Am J Cardiol. 2019; 123(11): 1739–1744.
- Saleh ZT, Alraoush AT, Aqel AA, et al. Sex differences in the association between inflammation and event-free survival in patients with heart failure. J Cardiovasc Nurs. 2021 [Epub ahead of print].
- Reina-Couto M, Pereira-Terra P, Quelhas-Santos J, et al. Inflammation in human heart failure: major mediators and therapeutic targets. Front Physiol. 2021; 12: 746494.
- Budzyński J, Tojek K, Wustrau B, et al. The "cholesterol paradox" among inpatients - retrospective analysis of medical documentation. Arch Med Sci Atheroscler Dis. 2018; 3: e46–e57.